

Press Release

Changes of Representative Director and Directors

TOKYO, April 27, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided changes of Representative Director and Directors as stated below. These changes are subject to approval at the 17th Term Annual Shareholders Meeting and decision at the Board of Directors meeting, both scheduled on June 20, 2022.

1. Change of Representative Director

- Representative Director to be retired
Yoshihiko Hatanaka
(Current) Representative Director and Chairman of the Board
- Effective date of the change: June 20, 2022
- Reason for the change: Mr. Hatanaka has committed the company as a representative director and decided to hand over the duties to the current management for the company’s future growth as he judged that it would be appropriate timing.

2. Candidates for Directors

(Excluding Directors who are Audit & Supervisory Committee Members)

Name		Current Position
Kenji Yasukawa	Reelection	Representative Director, President and CEO
Naoki Okamura	Reelection	Representative Director, Executive Vice President and Chief Strategy Officer (CStO)
Mamoru Sekiyama	Outside Reelection	Outside Director and Audit & Supervisory Committee Member, A.D. Works Group Co., Ltd.
Hiroshi Kawabe	Outside Reelection	Professor Emeritus, Keio University President, Foundation for Promotion of Medical Training
Takashi Tanaka	Outside Reelection	Representative Director, Chairman of the Board, KDDI CORPORATION Director, Okinawa Cellular Telephone Company
Eriko Sakurai	Outside New Candidate	President and Representative Director, Dow Chemical Japan Limited Outside Director, Sumitomo Mitsui Financial Group, Inc. Outside Director, Kao Corporation

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

3. Candidates for Directors who are Audit & Supervisory Committee Members

Name		Current Position
Toru Yoshimitsu	Reelection	Director (Full-time Audit & Supervisory Committee Member)
Raita Takahashi	Outside Reelection	Representative, TAKAHASHI Accounting & Tax office Outside Audit & Supervisory Board Member, Alpha Group Inc. Representative Director, Yoshida Management Co. Ltd.
Mika Nakayama	Outside New Candidate	Director, Senior Executive Officer, General Manager of Sustainability Promotion Department, JSR Corporation

The current position of the candidate for outside Director describes significant concurrent positions at other organizations pursuant to the Companies Act.

4. Directors to be retired

Director	Yoshihiko Hatanaka
Outside Director	Tatsuro Ishizuka
Outside Director, Audit & Supervisory Committee Member	Hiroo Sasaki

5. The Board of Directors as from June 20, 2022 (planned)

Kenji Yasukawa (Representative Director, President and CEO, Chairman of the Board)

Naoki Okamura (Representative Director, Executive Vice President)

Mamoru Sekiyama (Outside Director)

Hiroshi Kawabe (Outside Director)

Takashi Tanaka (Outside Director)

Eriko Sakurai (Outside Director)

Toru Yoshimitsu (Director, Audit & Supervisory Committee Member)

Haruko Shibumura (Outside Director, Audit & Supervisory Committee Member)

Raita Takahashi (Outside Director, Audit & Supervisory Committee Member)

Mika Nakayama (Outside Director, Audit & Supervisory Committee Member)

About Astellas

Astellas Pharma Inc., is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
+81-3-3244-3201